Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 2, 2026World Journal of Gastrointestinal Pharmacology and TherapeuticsOpen Access

Nor-ursodeoxycholic acid in hepatobiliary diseases: A narrative review

View Full Paper
Ask AI
Bookmark
Share

Authors

SMSayan MalakarNSNeha SoodSGSuprabhat Giri

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Malakar et al. (2026) studied this question.

synapsesocial.com/papers/6ab7623245352bcff29397cahttps://doi.org/10.4292/wjgpt.120122
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #2009 · 727 citations
  2. 2Bile Acid Physiology2017 · 563 citations
  3. 3Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 <scp>ESSENCE</scp> Trial2024 · 139 citations
  4. 4A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis2024 · 1,972 citations
  5. 5A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis2016 · 1,137 citations